Synchronous pancreatic and gastric metastasis from an ovarian adenocarcinoma diagnosed by endoscopic ultrasound-guided fine-needle aspiration Metastasis of ovarian carcinoma to the stomach [1 -5] or pancreas [6, 7] is uncommon. Furthermore, synchronous metastasis of ovarian adenocarcinoma to the stomach and pancreas has never been reported. We report here the detection of synchronous metastasis to both the stomach and pancreas from a resected ovarian papillary serous cystadenocarcinoma. At 25 months after gynecological surgery, a gastric submucosal mass and pancreatic masses were noted on follow-up computed tomography in an asymptomatic 51-year-old woman. Contrast-enhanced computed tomography showed a 4.6 × 4.2-cm submucosal mass in the gastric antrum (• " Fig. 1 a) and a 1.0 × 1.0-cm mass in the pancreatic body (• " Fig. 1 b) . The serum cancer antigen 125 (CA-125) level was high (89 U/mL; normal < 35 U/mL). The patient underwent esophagogastroduodenoscopy (EGD), which showed a 3-cm subepithelial mass at the antrum (• " Fig. 2) . Endoscopic ultrasound (EUS) demonstrated that the lesion was located mainly in the fourth layer (• " Fig. 3) . In addition, two pancreatic lesions, measuring 7 × 5 mm and 4 × 3 mm, were identified in the pancreatic body (• " Fig. 4) . EUS-guided fine-needle aspiration (EUS-FNA) of the gastric and pancreatic lesions was performed, and microscopic examination showed a group of cells with rounded borders and round to oval nuclei in a papillary arrangement (• " Fig. 5 ).
Follow-up abdominal contrastenhanced computed tomography in an asymptomatic 51-yearold woman at 25 months after gynecological surgery. a A 4.6 × 4.2-cm intramural mass (yellow arrows) in the gastric antrum is suggestive of a gastric submucosal tumor. b A 1.0 × 1.0-cm mass (yellow arrows) in the pancreatic body exhibits slight enhancement in the early phase. Immunohistochemical study revealed positivity for cytokeratin 7 (+ +), CA-125 (+), estrogen receptor (+ +), progesterone receptor (+), and CD56 (+ +), and negativity for cytokeratin 20 (-) and CDX-2 (-). The pathological features were similar to those of the previous ovarian lesion. The final pathological diagnosis was metastatic tumor from a primary ovarian carcinoma.
In conclusion, a possible diagnosis of gastric and pancreatic metastasis of ovarian papillary serous adenocarcinoma should be kept in mind in a patient with an unknown primary lesion, even one with a remote history of ovarian malignancy. EUS-FNA in conjunction with immunohis-tochemistry is a useful tool for diagnosing metastatic lesions. 
